Reported Earnings • May 21
First quarter 2026 earnings released: EPS: kr0.72 (vs kr0.12 loss in 1Q 2025) First quarter 2026 results: EPS: kr0.72 (up from kr0.12 loss in 1Q 2025). Revenue: kr98.9m (up kr88.1m from 1Q 2025). Net income: kr65.2m (up kr75.4m from 1Q 2025). Profit margin: 66% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue. Announcement • Mar 10
Nanologica AB (publ), Annual General Meeting, May 21, 2026 Nanologica AB (publ), Annual General Meeting, May 21, 2026, at 10:00 W. Europe Standard Time. Location: advokatfirman lindahls -, premises at smalandsgatan 16, stockholm Sweden Announcement • Mar 05
Nanologica AB (Publ) Appoints Jeremie Trochu as Member of the Board of Directors Nanologica AB (publ) at its Extraordinary general meeting held on March 4, 2026 resolved to increase the number of board members from five to six, and to elect Jeremie Trochu as a new member of the board of directors for the period until the end of the next annual general meeting. Announcement • Oct 14
Nanologica AB (publ), Annual General Meeting, Sep 30, 2026 Nanologica AB (publ), Annual General Meeting, Sep 30, 2026. Announcement • May 23
Flerie Invest AB proposed to acquire remaining 56.74% stake in Nanologica AB (publ) (OM:NICA) for SEK 50.1 million. Flerie Invest AB proposed to acquire remaining 56.74% stake in Nanologica AB (publ) (OM:NICA) for SEK 50.1 million on May 23, 2025. A cash consideration valued at SEK 1 per share will be paid by Flerie Invest AB for 50,134,455. Upon completion, Flerie Invest AB will own 100% stake in Nanologica AB (publ). The transaction will be financed through existing funds in Flerie. If Flerie becomes the holder of shares to such an extent that they represent more than 90% of the total number of shares in Nanologica, Flerie intends to request compulsory acquisition of the remaining shares in Nanologica.
The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is July 15, 2025.
Setterwalls Advokatbyrå Ab acted as legal advisor for Flerie Invest AB. Announcement • Nov 12
Nanologica AB (publ), Annual General Meeting, May 22, 2025 Nanologica AB (publ), Annual General Meeting, May 22, 2025. Location: stockholm Sweden New Risk • Nov 10
New major risk - Negative shareholders equity The company has negative equity. Total equity: -kr8.8m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr66m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-kr8.8m). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m (kr8.7m revenue, or US$806k). Market cap is less than US$10m (€7.49m market cap, or US$8.02m). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding). Reported Earnings • Nov 10
Third quarter 2024 earnings released: kr0.54 loss per share (vs kr0.32 loss in 3Q 2023) Third quarter 2024 results: kr0.54 loss per share (further deteriorated from kr0.32 loss in 3Q 2023). Revenue: kr782.0k (up 129% from 3Q 2023). Net loss: kr23.7m (loss widened 105% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings. New Risk • Oct 01
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €8.75m (US$9.75m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr54m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m (kr8.5m revenue, or US$837k). Market cap is less than US$10m (€8.75m market cap, or US$9.75m). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding). Announcement • Sep 24
Nanologica AB (Publ) Elects Alexandra Blomberg Montgomery as New Member of the Board of Directors Nanologica AB (publ) at its extraordinary general meeting held on September 23, 2024, resolved to expand the board of directors from five to six members and to elect Alexandra Blomberg Montgomery as a new member of the board of directors for the period until the end of the next annual general meeting. New Risk • Aug 05
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr54m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr54m free cash flow). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m (kr8.5m revenue, or US$803k). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (€20.4m market cap, or US$22.2m). Reported Earnings • Jul 07
Second quarter 2024 earnings released: kr0.25 loss per share (vs kr0.41 loss in 2Q 2023) Second quarter 2024 results: kr0.25 loss per share (improved from kr0.41 loss in 2Q 2023). Revenue: kr2.21m (up 35% from 2Q 2023). Net loss: kr11.1m (loss narrowed 24% from 2Q 2023). Revenue is forecast to grow 80% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings. New Risk • Jun 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr61m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 30% per year over the past 5 years. Revenue is less than US$1m (kr8.0m revenue, or US$765k). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (€23.3m market cap, or US$25.4m). Reported Earnings • Apr 28
First quarter 2024 earnings released: kr0.46 loss per share (vs kr0.34 loss in 1Q 2023) First quarter 2024 results: kr0.46 loss per share (further deteriorated from kr0.34 loss in 1Q 2023). Net loss: kr16.8m (loss widened 39% from 1Q 2023). Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Announcement • Apr 12
Nanologica AB (publ) Announces Chief Operating Officer Changes Nanologica AB (publ) announced that Åsa Bergström will take over as COO at the company on May 1 after the current COO Anna-Karin Renström leaves the company on April 26. Åsa Bergström also joins Nanologica's management team. Åsa Bergström, born 1964, holds a Master of Science in Chemical Engineering and Biotechnology from KTH Royal Institute of Technology and an MBA Global Executive Management from Copenhagen Business School. Åsa joins Nanologica from pharmaceutical contract manufacturer Recipharm where she held the position of Director Global Sustainability. Åsa has prior held several roles at Recipharm as Site Manager Recipharm Development, Director Corporate Projects, as well as Environmental Manager, and has worked with system management, aquisitions, and project management for factory constructions at Recipharm. Åsa will take up her position on May 1 and will join Nanologica's management team. New Risk • Mar 30
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 22% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-kr1.9m). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (kr4.7m revenue, or US$438k). Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (€25.9m market cap, or US$28.0m). Reported Earnings • Mar 26
Full year 2023 earnings released: kr2.08 loss per share (vs kr1.84 loss in FY 2022) Full year 2023 results: kr2.08 loss per share (further deteriorated from kr1.84 loss in FY 2022). Net loss: kr75.2m (loss widened 36% from FY 2022). Revenue is forecast to grow 64% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Germany. Reported Earnings • Feb 04
Full year 2023 earnings released: kr2.08 loss per share (vs kr1.84 loss in FY 2022) Full year 2023 results: kr2.08 loss per share (further deteriorated from kr1.84 loss in FY 2022). Net loss: kr75.2m (loss widened 36% from FY 2022). Revenue is forecast to grow 97% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Biotechs industry in Germany. Board Change • Feb 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Director Thomas Eldered was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Jan 30
Nanologica AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 54.2 million. Nanologica AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 54.2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 8,029,630
Price\Range: SEK 6.75
Transaction Features: Rights Offering New Risk • Dec 21
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr59m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr59m free cash flow). Earnings have declined by 27% per year over the past 5 years. Revenue is less than US$1m (kr5.9m revenue, or US$582k). Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (€32.3m market cap, or US$35.3m). Reported Earnings • Oct 31
Third quarter 2023 earnings released: kr0.32 loss per share (vs kr0.39 loss in 3Q 2022) Third quarter 2023 results: kr0.32 loss per share. Net loss: kr11.6m (loss widened 5.2% from 3Q 2022). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Announcement • Oct 29
Nanologica AB (publ), Annual General Meeting, May 16, 2024 Nanologica AB (publ), Annual General Meeting, May 16, 2024. Announcement • Oct 27
Nanologica AB (publ) Announces Nomination Committee for the Annual General Meeting 2024 Nanologica AB (publ) announced that in accordance with the resolution at the Annual General Meeting on May 4, 2023, the chairman of the board has contacted Nanologica’s three owners or ownership groups in terms of votes as of September 30, 2023, each of whom has appointed a representative to constitute the nomination committee of Nanologica AB for the 2024 AGM. The nomination committee for Nanologica AB's 2024 AGM thus consists of the following three members: Carl-Johan Spak (Flerie Invest AB); Lennart Francke (Swedbank Robur Microcap); Kalle Olby (Vega Bianca AB). New Risk • Oct 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (kr7.2m revenue, or US$655k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr57m). Currently unprofitable and not forecast to become profitable over next 2 years (kr3.1m net loss in 2 years). Share price has been volatile over the past 3 months (7.1% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (€34.8m market cap, or US$36.7m). New Risk • Jul 09
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -kr57m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m (kr7.4m revenue, or US$686k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr57m). Currently unprofitable and not forecast to become profitable over next 2 years (kr3.1m net loss in 2 years). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (€35.5m market cap, or US$38.9m). Reported Earnings • Jul 07
Second quarter 2023 earnings released: kr0.41 loss per share (vs kr0.48 loss in 2Q 2022) Second quarter 2023 results: kr0.41 loss per share. Net loss: kr14.7m (loss widened 8.9% from 2Q 2022). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Germany. Buying Opportunity • May 23
Now 22% undervalued Over the last 90 days, the stock is up 6.4%. The fair value is estimated to be €1.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 32% over the last 3 years. Earnings per share has declined by 20%. Revenue is forecast to grow by 1,970% in 2 years. Earnings is forecast to grow by 87% in the next 2 years. Announcement • May 09
Chief Scientific Officer, Gary Pitcairn Will Leave Nanologica AB (publ) Nanologica AB (publ) has decided to focus on Chromatography and the management team is adapted to reflect the new business focus. In order to create the best conditions for success in preparative chromatography, the company's operations are focused on Chromatography and the Drug Development operations are down- prioritized and placed in subsidiaries for future opportunities. The management team is adapted to reflect this and CSO Gary Pitcairn will leave the company for new opportunities. Reported Earnings • Apr 30
First quarter 2023 earnings released: kr0.34 loss per share (vs kr0.56 loss in 1Q 2022) First quarter 2023 results: kr0.34 loss per share (improved from kr0.56 loss in 1Q 2022). Net loss: kr12.1m (loss narrowed 24% from 1Q 2022). Revenue is forecast to grow 86% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Germany. Reported Earnings • Feb 12
Full year 2022 earnings released: kr1.84 loss per share (vs kr1.60 loss in FY 2021) Full year 2022 results: kr1.84 loss per share (further deteriorated from kr1.60 loss in FY 2021). Net loss: kr55.2m (loss widened 23% from FY 2021). Revenue is forecast to grow 102% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Board Change • Feb 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Director Thomas Eldered was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Breakeven Date Change • Nov 16
No longer forecast to breakeven The analyst covering Nanologica no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr8.20m in 2023. New forecast suggests the company will make a loss of kr7.00m in 2024. Reported Earnings • Aug 21
Second quarter 2022 earnings released: kr0.48 loss per share (vs kr0.33 loss in 2Q 2021) Second quarter 2022 results: kr0.48 loss per share (down from kr0.33 loss in 2Q 2021). Net loss: kr13.5m (loss widened 46% from 2Q 2021). Over the next year, revenue is forecast to grow 715%, compared to a 10% growth forecast for the Biotechs industry in Germany. Reported Earnings • May 05
First quarter 2022 earnings released: kr0.56 loss per share (vs kr0.28 loss in 1Q 2021) First quarter 2022 results: kr0.56 loss per share (down from kr0.28 loss in 1Q 2021). Revenue: kr754.0k (down 88% from 1Q 2021). Net loss: kr15.9m (loss widened 103% from 1Q 2021). Over the next year, revenue is forecast to grow 298%, compared to a 28% growth forecast for the industry in Germany. Breakeven Date Change • Apr 27
No longer forecast to breakeven The analyst covering Nanologica no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr8.20m in 2023. New forecast suggests the company will make a loss of kr8.70m in 2024. Reported Earnings • Mar 15
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: kr1.60 loss per share (down from kr0.93 loss in FY 2020). Revenue: kr14.7m (down 20% from FY 2020). Net loss: kr44.8m (loss widened 102% from FY 2020). Revenue missed analyst estimates by 7.1%. Over the next year, revenue is forecast to grow 42%, compared to a 76% growth forecast for the pharmaceuticals industry in Germany. Reported Earnings • Feb 09
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: kr1.60 loss per share (down from kr0.93 loss in FY 2020). Revenue: kr15.8m (down 14% from FY 2020). Net loss: kr44.8m (loss widened 102% from FY 2020). Revenue missed analyst estimates by 7.1%. Over the next year, revenue is forecast to grow 245%, compared to a 62% growth forecast for the pharmaceuticals industry in Germany. Breakeven Date Change • Nov 24
No longer forecast to breakeven The analyst covering Nanologica no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr8.20m in 2023. New forecast suggests the company will make a loss of kr18.4m in 2023. Reported Earnings • Nov 03
Third quarter 2021 earnings released: kr0.45 loss per share (vs kr0.32 loss in 3Q 2020) The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: kr2.95m (down 4.5% from 3Q 2020). Net loss: kr12.5m (loss widened 77% from 3Q 2020). 
